Volume 2, Issue 4

Steroids, Dyspnea, and COVID: Clinical Challenges in COPD Management

In this issue:

In early 2022, the state of the art for managing patients with COPD continues to present challenges. When, how, and in whom are inhaled steroids the most effective way to reduce exacerbations? Are the GOLD guidelines still relevant? What do patients with COPD need to know about the dangers and long-term effects of COVID-19 infection? 

These are some of the questions we discuss with our guest, Dr. Nirupama Putcha from the Division of Pulmonology and Critical Care at the Johns Hopkins University School of Medicine, in this issue of ePulmonology Review. 

Learning objectives:

  • Discuss preventative strategies and treatments for individuals with COPD at risk for exacerbations. 
  • Describe preventative strategies and treatments for individuals with COPD with dyspnea and exercise limitation, and special considerations during the COVID pandemic. 

Author:

Nirupama Putcha, MD, MHS
Nirupama Putcha, MD, MHS

Assistant Professor of Medicine
Division of Pulmonary and Critical Care Medicine
Johns Hopkins School of Medicine
Baltimore, Maryland

Program Directors:

Gregory B. Diette, MD

Professor of Medicine, Epidemiology and Environmental Health Sciences
Johns Hopkins University School of Medicine
Baltimore, Maryland

Christine Smith, RN, MSN

Senior Clinic Nurse Coordinator
Johns Hopkins Medicine
Baltimore, Maryland

Length of activity:

0.5 hour Physicians
0.5 contact hour Nurses

Launch date: March 30, 2022
Expiration date: March 29, 2024